Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by XTX Topco Ltd

XTX Topco Ltd lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,722 shares of the company’s stock after selling 2,818 shares during the period. XTX Topco Ltd’s holdings in Medpace were worth $1,237,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares in the last quarter. HBK Sorce Advisory LLC boosted its stake in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after acquiring an additional 29 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC increased its position in shares of Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after purchasing an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. lifted its holdings in shares of Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after purchasing an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. Truist Financial decreased their price objective on Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a report on Wednesday, April 9th. Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday, March 24th. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Finally, TD Cowen downgraded shares of Medpace from a “buy” rating to a “hold” rating and lowered their target price for the company from $370.00 to $328.00 in a report on Monday. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $357.50.

Medpace Stock Performance

MEDP stock opened at $305.28 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $272.00 and a 1 year high of $459.77. The firm has a market cap of $9.23 billion, a P/E ratio of 24.17, a PEG ratio of 3.81 and a beta of 1.46. The stock’s 50 day moving average price is $322.58 and its 200 day moving average price is $334.29.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.